- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of refractory thyroid cancer
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 25, Issue 4, Pages R209-R223
Publisher
Bioscientifica
Online
2018-01-26
DOI
10.1530/erc-17-0542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Timing of multikinase inhibitor initiation in differentiated thyroid cancer
- (2017) Marcia S Brose et al. ENDOCRINE-RELATED CANCER
- Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid
- (2017) Makoto Tahara et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
- (2017) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
- (2017) Marcia S. Brose et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124 I PET/CT–Based Dosimetry for 131 I Therapy of Metastatic Differentiated Thyroid Cancer
- (2017) Donika Plyku et al. JOURNAL OF NUCLEAR MEDICINE
- The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer
- (2016) Marie Terroir et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
- (2016) Bruce Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer
- (2016) Livia Lamartina et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer
- (2016) Désirée Deandreis et al. JOURNAL OF NUCLEAR MEDICINE
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- (2016) Marcia S Brose et al. LANCET ONCOLOGY
- Biologic and Clinical Perspectives on Thyroid Cancer
- (2016) James A. Fagin et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E-Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
- (2015) Ramona Dadu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials
- (2015) Massimo Di Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study
- (2015) J. Nagarajah et al. JOURNAL OF NUCLEAR MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Postoperative Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: An Important Imaging Modality in Patients with Aggressive Histology of Differentiated Thyroid Cancer
- (2015) Camila Nascimento et al. THYROID
- BRAF Inhibitor Dabrafenib in Patients with MetastaticBRAF-Mutant Thyroid Cancer
- (2015) Gerald S. Falchook et al. THYROID
- Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments
- (2014) Laura D. Locati et al. CANCER
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
- (2014) S. M. Rothenberg et al. CLINICAL CANCER RESEARCH
- Treatment With Thyroid Hormone
- (2014) Bernadette Biondi et al. ENDOCRINE REVIEWS
- Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network
- (2014) Marie-Hélène Massicotte et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma
- (2014) Elena-Daphne Thies et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
- (2014) Ramona Dadu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
- (2014) L. M. Kelly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
- (2014) Maria E. Cabanillas et al. THYROID
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer
- (2014) Martin Schlumberger et al. Lancet Diabetes & Endocrinology
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Metastatic mechanisms in follicular cell-derived thyroid cancer
- (2013) John E Phay et al. ENDOCRINE-RELATED CANCER
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
- (2013) Mabel Ryder et al. PLoS One
- Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer
- (2013) Dean P. Blevins et al. THYROID
- Sorafenib in metastatic thyroid cancer
- (2012) Jaume Capdevila et al. ENDOCRINE-RELATED CANCER
- Unusual Short-Term Complete Response to Two Regimens of Cytotoxic Chemotherapy in a Patient with Poorly Differentiated Thyroid Carcinoma
- (2012) Geneviève Crouzeix et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer
- (2012) Azeez Farooki et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Bone-Targeted Agents on Cancer Progression and Mortality
- (2012) R. Coleman et al. JNCI-Journal of the National Cancer Institute
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell–Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy 131I Whole-Body Scans
- (2012) Mona M. Sabra et al. THYROID
- One Month Is Sufficient for Urinary Iodine to Return to Its Baseline Value After the Use of Water-Soluble Iodinated Contrast Agents in Post-Thyroidectomy Patients Requiring Radioiodine Therapy
- (2012) Rosália P. Padovani et al. THYROID
- The Treatment of Differentiated Thyroid Cancer in Children: Emphasis on Surgical Approach and Radioactive Iodine Therapy
- (2011) Scott A. Rivkees et al. ENDOCRINE REVIEWS
- BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas
- (2011) Cosimo Durante et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH
- (2011) H. Tala et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy of DosimetricVersusEmpiric Prescribed Activity of131I for Therapy of Differentiated Thyroid Cancer
- (2011) Joanna Klubo-Gwiezdzinska et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
- (2011) Jean-Philippe Spano et al. MEDICAL ONCOLOGY
- Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma
- (2011) Bernard Caillou et al. PLoS One
- In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response
- (2011) Fernanda Vaisman et al. THYROID
- Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy
- (2011) Akira Miyauchi et al. THYROID
- Multidisciplinary Treatment and Survival of Patients with Vertebral Metastases from Thyroid Carcinoma
- (2011) Gerald M.Y. Quan et al. THYROID
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma
- (2010) S.I. Sherman CLINICAL ONCOLOGY
- Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
- (2010) D. Deandreis et al. ENDOCRINE-RELATED CANCER
- Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer
- (2010) Michael B. Bass et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Role of FDG PET/CT and Chest CT in the Follow-up of Lung Lesions Treated with Radiofrequency Ablation
- (2010) Désirée Deandreis et al. RADIOLOGY
- Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
- (2010) Mingzhao Xing THYROID
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1
- (2009) J. C. Ricarte-Filho et al. CANCER RESEARCH
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma
- (2008) Michael Rivera et al. CANCER
- Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer
- (2008) M. Ryder et al. ENDOCRINE-RELATED CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started